

Influenza A Virus, H7N9 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/I2E24C0B62D0EN.html>

Date: December 2022

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: I2E24C0B62D0EN

Abstracts

Influenza A Virus, H7N9 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections - Drugs In Development, 2022, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape.

Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 9 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 3 and 3 molecules, respectively.

Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Influenza A Virus, H7N9

Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Influenza A Virus, H7N9 Subtype Infections - Overview
Influenza A Virus, H7N9 Subtype Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Influenza A Virus, H7N9 Subtype Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Influenza A Virus, H7N9 Subtype Infections - Companies Involved in Therapeutics Development
AIM ImmunoTech Inc
AusBio Ltd
Beijing Tiantan Biological Products Co Ltd
Celdara Medical LLC
Cocrystal Pharma Inc
Codagenix Inc
CSL Ltd
EpiVax Inc
Greffex Inc
GSK plc
Hualan Biological Bacterin Co Ltd
Inovio Pharmaceuticals Inc
Medicago Inc
NanoViricides Inc
New Amsterdam Sciences Inc
Ology Bioservices Inc
Pneumagen Ltd
TaiGen Biotechnology Co Ltd
Influenza A Virus, H7N9 Subtype Infections - Drug Profiles
CC-42344 - Drug Profile
Product Description

Mechanism Of Action

CDX-H7N9 - Drug Profile

Product Description

Mechanism Of Action

CMBT-1 - Drug Profile

Product Description

Mechanism Of Action

GSK-3206641A - Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] (monovalent) vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] (monovalent) vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] (split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

influenza [strains A/H7N9] (split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

interferon alfa-n3 - Drug Profile

Product Description

Mechanism Of Action

MD-2009 - Drug Profile

Product Description

Mechanism Of Action

MDG-7529 - Drug Profile

Product Description

Mechanism Of Action

NAS-911 - Drug Profile

Product Description

Mechanism Of Action

Neumifil - Drug Profile

Product Description

Mechanism Of Action

NVIN-1 - Drug Profile

Product Description

Mechanism Of Action

NVIN-2 - Drug Profile

Product Description

Mechanism Of Action

Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Influenza Virus Infections - Drug Profile

Product Description

Mechanism Of Action

TG-1000 - Drug Profile

Product Description

Mechanism Of Action

Influenza A Virus, H7N9 Subtype Infections - Dormant Projects

Influenza A Virus, H7N9 Subtype Infections - Discontinued Products

Influenza A Virus, H7N9 Subtype Infections - Product Development Milestones

Featured News & Press Releases

Jan 10, 2019: Development and Industrialization Construction Project of Quadrivalent Influenza Vaccine of Hualan Biological Bacterin

May 23, 2018: Application of Quadrivalent Influenza Vaccine (QIV)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by AIM ImmunoTech Inc, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by AusBio Ltd, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Beijing Tiantan Biological Products Co Ltd, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Celdara Medical LLC, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Cocystal Pharma Inc, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Codagenix Inc, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by CSL Ltd, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by EpiVax Inc, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Greffex Inc, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by GSK plc, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Hualan Biological Bacterin Co Ltd, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medicago Inc, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by NanoViricides Inc, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by New Amsterdam Sciences Inc, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Ology Bioservices Inc, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Pneumagen Ltd, 2022

Influenza A Virus, H7N9 Subtype Infections - Pipeline by TaiGen Biotechnology Co Ltd, 2022

Influenza A Virus, H7N9 Subtype Infections - Dormant Projects, 2022

Influenza A Virus, H7N9 Subtype Infections - Dormant Projects, 2022 (Contd..1)

Influenza A Virus, H7N9 Subtype Infections - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Influenza A Virus, H7N9 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/I2E24C0B62D0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I2E24C0B62D0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

